NYSE:ALife Sciences
Will Agilent’s (A) Native-Read Sequencing Push with Wasatch BioLabs Redefine Its Genomics Narrative?
In December 2025, Wasatch BioLabs announced a co-marketing agreement with Agilent Technologies to pair Agilent’s SureSelect and Avida enrichment chemistries with WBL’s Oxford Nanopore-based Direct Targeted Methylation Sequencing platform, enabling precise, custom native-read targeting of genomic and cell-free DNA for research and clinical applications.
The collaboration aims to broaden access to scalable, cost-efficient native-read multi-omic assays, especially for liquid biopsy, oncology,...